New vaccine study aims to better protect vulnerable kids from pneumonia

NCT ID NCT07252791

Recruiting now ⭐️ VACCINE ⭐️ Sponsor: University of Sao Paulo General Hospital Source: ClinicalTrials.gov ↗

First seen Dec 08, 2025 · Last updated May 25, 2026 · Updated 21 times

Summary

This study is testing a 20-valent pneumococcal vaccine (PCV20) in 114 children, adolescents, and young adults aged 2-25 who have autoimmune rheumatic diseases like juvenile arthritis. The goal is to see if the vaccine triggers a strong immune response and is safe, especially for those on immune-suppressing medications. Participants will receive the vaccine based on their past shots, and researchers will track antibody levels and side effects for up to 6 months.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AUTOIMMUNE RHEUMATOLOGIC DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Hospital das Clinics da Faculdade de Medicina da Universidade de Sao Paulo
RECRUITING

São Paulo, São Paulo, Brazil

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

AUTOIMMUNE RHEUMATOLOGIC DISEASE